|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Pioneering function of Isl1 in the epigenetic control of cardiomyocyte cell fate显示文摘Generation of widely differing and specialized cell types from a single totipotent zygote involves large-scale transcriptional changes and chromatin reorganization. Pioneer transcription factors play key roles in programming the epigenome and facilitating recruitment of additional regulatory factors during successive cell lineage specification and differentiation steps. Here we show that Isl1 acts as a pioneer factor driving cardiomyocyte lineage commitment by shaping the chromatin landscape of cardiac progenitor cells. Using an Isl1 hypomorphic mouse line which shows congenital heart defects, genome-wide profiling of Isl1 binding together with RNA- and ATAC-sequencing of cardiac progenitor cells and their derivatives, we uncover a regulatory network downstream of Isl1 that orchestrates cardiogenesis. Mechanistically, we show that Isl1 binds to compacted chromatin and works in concert with the Brg1-Baf60c-based SWI/SNF complex to promote permissive cardiac lineage-specific alterations in the chromatin landscape not only of genes with critical functions in cardiac progenitor cells, but also of cardiomyocyte structural genes that are highly expressed when Isl1 itself is no longer present. Thus, the Isl1/Brg1-Baf60c complex plays a crucial role in orchestrating proper cardiogenesis and in establishing epigenetic memory of cardiomyocyte fate commitment. | Rui Gao Xingqun Liang Sirisha Cheedipudi Julio Cordero Xue Jiang Qingquan Zhang Luca Caputo Stefan Günther Carsten Kuenne Yonggang Ren Shoumo Bhattacharya Xuejun Yuan Guillermo Barreto Yihan Chen Thomas Braun Sylvia M. Evans Yunfu Sun Gergana Dobreva | 2019 | Cell Research2019，29，6： | 5 |
| 2 | Cyclin-dependent kinase 4 is a novel target in micoRNA-195-mediated cell cycle arrest in bladder cancer cells显示文摘 | Yiwei Lin Jian Wu Hong Chen Yeqing Mao Yunfu Liu Qiqi Mao Kai Yang Xiangyi Zheng Liping Xie | 2012 | FEBS Letters2012，，4： | 2 |
| 3 | Global antimicrobial resistance:a system-wide comprehensive investigation using the Global One Health Index显示文摘Background:Antimicrobial resistance(AMR)is one of the top ten global public health challenges.However,given the lack of a comprehensive assessment of worldwide AMR status,our objective is to develop a One Health-based system-wide evaluation tool on global AMR.Methods:We have further developed the three-hierarchical Global One Health Index(GOHI)-AMR indicator scheme,which consists of five key indicators,17 indicators,and 49 sub-indicators,by incorporating 146 countries'data from diverse authoritative databases,including WHO's Global Antimicrobial Resistance and Use Surveillance System(GLASS)and the European CDC.We investigated the overall-or sub-rankings of GOHI-AMR at the international/regional/national levels for data preprocessing and score calculation utilizing the existing GOHI methodology.Additionally,a correlation analysis was conducted between the GOHI-AMR and other socioeconomic factors.Results:The average GOHI-AMR score for 146 countries is 38.45.As expected,high-income countries(HICs)outperform the other three income groups on overall rankings and all five key indicators of GOHI-AMR,whereas lowincome countries unexpectedly outperform upper-middle-income countries and lower-middle-income countries on the antibiotics-resistant key indicator(ARR)and ARR-subordinate indicators,including carbapenem-,β-lactam-,and quinolone resistance,and even HICs on aminoglycoside resistance.There were no significant differences among the four groups on the environmental-monitoring indicator(P>0.05).GOHI-AMR was positively correlated with gross domestic product,life expectancy,and AMR-related publications,but negatively with natural growth rate and chronic respiratory disease.In contrast to Cyprus,the remarkably lower prevalence of'ESKAPE pathogens'in high-scoring Sweden and Denmark highlights Europe's huge gaps.China and Russia outperformed the other three BRICS countries on all key indicators,particularly India's ARR and Brazil's AMR laboratory network and coordination capacity.Furthermore,significant internal disparities in carbapenem-resistant Klebsiella pneumoniae(CRKP)and methicillin-resistant Staphylococcus aureus(MRSA)prevalence were observed between China and the USA,with MRSA prevalence both gradually declining,whereas CRKP prevalence has been declining in the USA but increasing in China,consistent with higher carbapenems-related indicator'performance in USA.Conclusions:GOHI-AMR is the most comprehensive tool currently available for the assessment of AMR status worldwide.We discovered unique features impacting AMR in each country and offered precise recommendations to improve the capacity to tackle AMR in low-ranking countries. | Nan Zhou Zile Cheng Xiaoxi Zhang Chao Lv Chaoyi Guo Haodong Liu Ke Dong Yan Zhang Chang Liu Yunfu Chang Sheng Chen Xiaokui Guo Xiao-Nong Zhou Min Li Yongzhang Zhu | 2022 | Infectious Diseases of Poverty2022，11，4： | 2 |
| 4 | MicroRNA-204 is required for differentiation of human-derived cardiomyocyte progenitor cells显示文摘 | Junjie Xiao Dandan Liang Hong Zhang Ying Liu Dasheng Zhang Yi Liu Lei Pan Xiaoli Chen Pieter A. Doevendans Yunfu Sun Xingqun Liang Joost P.G. Sluijter Yi-Han Chen | 2012 | Journal of Molecular and Cellular Cardiology2012，，6： | 1 |
| 5 | Separation of silicon and silicon car-bide using an electrical field 显示文摘 | Wu Yunfu Chen Yuanming | 2009 | Separation and Purification Tech-nology2009，68，1： | 1 |
| 6 | Gate-tunable graphene spin valve显示文摘 | Cho S Chen Yunfu Fuhrer M S | 2007 | Appl Phys Lett2007，91，12： | 1 |
| 7 | Analysis of gas-particle flow characteristics in impinging streams显示文摘 | Liu Xiangdong Chen Yongping Chen Yunfu | 2014 | Chem Eng Process2014，79，： | 1 |
| 8 | Separation of silicon and silicon earbide using an electrical field 显示文摘 | Wu Yunfu Chen Yuanming | 2009 | Separation and purification technology2009，58，1： | 1 |
| 9 | Establishment and Application of an Indirect ELISA for Detection on Antibody of Haemophilus parasuis显示文摘[Objective]The aim was to establish an indirect ELISA for detection on antibody of Hps. [Method] The optimal conditions of indirect ELISA were selected and determined based on heat-resistant serotype 4 and 5 of Hps; specific,repeating and sensitive tests were conducted and 200 serums were detected. [Result]The optimal conditions were as follows: coating concentration of antigen at 10 μg /ml,and coating for 2 h at 37 °C; PBST containing 20 g /L of skim milk powder as blocking fluid for 30 min; serum dilution at 1∶ 80; reaction time of antigen for 45 min; dilution of secondary antibody at 1∶ 12 000 and effecting for 30 min; color development reaction for 15 min. [Conclusion] The established indirect ELISA is good in specificity and repetitiveness with higher sensitivity than that of indirect hemagglutination test; the results of clinic samples ( negative /positive serums) were in consistent with those detected with foreign ELISA kits. The established method can be made use of in serum antibody of Hps de- tection and seroepidemiology study. | ZHENG Nian-guang 1 ,LUO Man-ling 1,2 ,GAO Juan 1 ,HE Ling 2 ,XIA Fang 2 ,TAN Shi-yong 3 ,CHEN Rui-ai 1. South China Agricultural University,Guangzhou 510642,China 2. Guangdong Dahuanong Animal Health Products CO. LTD,Yunfu 527400,China 3. Guangdong Hu’nongwenshi Animal Husbandry CO. LTD,Yunfu 527400,China | 2012 | Animal Husbandry and Feed Science2012，4，2： | 1 |
| 10 | An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19显示文摘The global spread of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)requires an urgent need to find effective therapeutics for the treatment of coronavirus disease 2019(COVID-19).In this study,we developed an integrative drug repositioning framework,which fully takes advantage of machine learning and statistical analysis approaches to systematically integrate and mine large-scale knowledge graph,literature and transcriptome data to discover the potential drug candidates against SARS-CoV-2.Our in silico screening followed by wet-lab validation indicated that a poly-ADP-ribose polymerase 1(PARP1)inhibitor,CVL218,currently in Phase I clinical trial,may be repurposed to treat COVID-19.Our in vitro assays revealed that CVL218 can exhibit effective inhibitory activity against SARS-CoV-2 replication without obvious cytopathic effect.In addition,we showed that CVL218 can interact with the nucleocapsid(N)protein of SARS-CoV-2 and is able to suppress the LPS-induced production of several inflammatory cytokines that are highly relevant to the prevention of immunopathology induced by SARS-CoV-2 infection. | Yiyue Ge Tingzhong Tian Suling Huang Fangping Wan Jingxin Li Shuya Li Xiaoting Wang Hui Yang Lixiang Hong Nian Wu Enming Yuan Yunan Luo Lili Cheng Chengliang Hu Yipin Lei Hantao Shu Xiaolong Feng Ziyuan Jiang Yunfu Wu Ying Chi Xiling Guo Lunbiao Cui Liang Xiao Zeng Li Chunhao Yang Zehong Miao Ligong Chen Haitao Li Hainian Zeng Dan Zhao Fengcai Zhu Xiaokun Shen Jianyang Zeng | 2021 | Signal Transduction and Targeted Therapy2021，6，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员